News & Updates
Filter by Specialty:
Does ribavirin improve efficacy of SOF/VEL/VOX in HCV retreatment?
The combination of sofosbuvir, velpatasvir, and voxilaprevir (SOF/VEL/VOX) with or without ribavirin demonstrates efficacy for the retreatment of patients with hepatitis C virus (HCV) infection in whom prior direct-acting antiviral (DAA) treatment has failed, a study in Egypt has shown.
Does ribavirin improve efficacy of SOF/VEL/VOX in HCV retreatment?
24 Jul 2023
Metabolic surgery bests medical/lifestyle management for people with diabetes in the long run
Individuals with type 2 diabetes (T2D) may fare better with metabolic bariatric surgery, which confers more favourable long-term outcomes as compared with intensive medical and lifestyle management, based on the 7- and 12-year data from the ARMMS-T2D* trial.
Metabolic surgery bests medical/lifestyle management for people with diabetes in the long run
21 Jul 2023
Age, tumour size predict post-TACE complications in HCC patients
In patients with hepatocellular carcinoma (HCC), most complications following transarterial chemoembolization (TACE) involve minor postembolization syndrome, reveals a study presented at EASL 2023. The incidence of major complications is high at 25 percent, with a 1.8-percent death rate.
Age, tumour size predict post-TACE complications in HCC patients
21 Jul 2023
Phase III data support long-term efficacy of TAF against HBV
Two phase III studies presented at EASL 2023 reflected the long-term efficacy of tenofovir alafenamide (TAF) for individuals with HBeAg*-positive and HBeAg-negative chronic hepatitis B virus (HBV).
Phase III data support long-term efficacy of TAF against HBV
18 Jul 2023
Advanced liver fibrosis a red flag for poor outcomes in T2D
Among individuals with type 2 diabetes (T2D), the risk of poor outcomes such as heart failure and hospitalizations is high in the presence of advanced liver fibrosis, according to a study.
